Search Studies
Research studies are looking for volunteers just like you. Both healthy volunteers and participants with specific health conditions are needed to help answer important questions impacting the health of our friends and family. Join us to improve the health of others.
-
A Depression Study Examining the Effects of Lumateperone in Treatment-Resistant Depression
Official Title A Randomized, Double-Blind, Placebo-controlled Multicenter Study to Assess the
Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of
Patients with Major Depressive DisorderPurpose
Depression is one of the most common mental health issues worldwide. Many people with major depressive disorder (MDD) take antidepressant medications that do not provide enough of a response to ease their depressive symptoms.
The primary objective of this study is to evaluate the benefit of Lumateperone 42 mg administered once daily compared with placebo as adjunctive treatment to antidepressant therapy (ADT) in patients with Major Depressive Disorder (MDD) who have an inadequate response to ongoing ADT.
Could this study be right for you?
You may be able to take part if you:
• are 18–65 years of age
• have a confirmed diagnosis of Major Depressive Disorder (MDD)
• feel that your current antidepressant medication is not working well
• Has tried 2 or more antidepressant medication in the current episode of depression
Other criteria will need to be met to confirm your eligibility for this study.
Age Range
18 - 65 years -
A First-in-human Study of a New Gene Therapy (AMT-260) in Adults with Unilateral Refractory Mesial Temporal Lobe Epilepsy (MTLE)
Official Title A Multi-center, Phase 1/2a, First-in-human (FIH) Study Investigating the Safety, Tolerability, and Efficacy of AMT-260 in Adults with Unilateral Refractory Mesial Temporal Lobe Epilepsy (MTLE) Administered via Magnetic Resonance Imaging (MRI)-guided Convection-enhanced Delivery (CED)Purpose
You are being invited to participate in a study about mesial temporal lobe epilepsy (MTLE) on only 1 side (unilateral) of the brain that has not responded to medication (refractory).
The study will test AMT-260, which is a new gene therapy under investigation for use in treating people like you with MTLE. It is not yet approved as a drug for treating MTLE. It can only be used in a study like this one. This is the first time this gene therapy will be used in humans. It has previously been studied in animals.
AMT-260 is a gene therapy designed to reduce the electrical signals between nerve cells (neurons) in the parts of your brain where nerve cells are abnormally connected. This reduces the extra electrical signals that happen at the same time and is intended to reduce your seizure activity.
The overall goals of this study are:
- To observe whether participants have any side effects from AMT-260 or from the procedure to deliver AMT-260 into the brain and how well participants tolerate any side effects that may occur.
- To measure if participants have changes in:
- frequency of their seizures
- how their seizures affect their life
- how the human body takes up and removes AMT-260
- To find the best dose of AMT-260 for future participants to ensure clinical benefit with minimal or no side effects.
Could this study be right for you?
Adult, 18-65 years of age, inclusive, capable of giving informed consent.
Written informed consent is given freely after the nature of the study has been explained to the participant and the completion of data disclosure.
Willingness to undergo necessary surgical procedures.
Diagnosis of unilateral refractory MTLE for ≥360 days, confirmed by an Epilepsy Monitoring Unit.Additional Eligibility Criteria to be assessed by neurosurgery team, and as described in the study protocol.
Age Range
18 - 65 years -
Social Abilities and Aging Study
Official Title Progression of Social Cognitive Deficits in Mid- and Late-Life Schizophrenia Spectrum DisordersPurpose
This research is being done to investigate the effects of age on social cognition in schizophrenia spectrum disorder. The study also hopes to examine potential neural bases of social cognition. The findings of the research will help develop effective treatment strategies by identifying who, when, and how to intervene.
Could this study be right for you?
Patients:
- Diagnosis of a schizophrenia spectrum disorder (includes schizophrenia, schizoaffective disorder, bipolar disorder with psychotic features, schizophreniform disorder, unspecified or other-specified psychotic disorders)
Healthy Controls:
- No history of any psychotic disorder
- No psychiatric diagnosis in the last 5 years
- Not taking psychotropic medication
Age Range
35 - 75 years -
IMPROVE-AD Trial: IMPRoving Outcomes in Vascular DisEase
Official Title IMPROVE-AD Trial: IMPRoving Outcomes in Vascular DisEase – Aortic DissectionPurpose
The goal of this study is to figure out the best way to treat type aortic dissection. An aortic dissection is a tear in the wall of the aorta. The aorta is a big blood vessel that carries blood from your heart to the rest of your body. Individuals with this problem usually get medicine or a special repair procedure. This procedure is called thoracic endovascular aortic repair (TEVAR). TEVAR is a procedure where a metal tube (called a stent), is inserted in the damaged part of the aorta. The study is being done to figure out which treatment works better. The results of the study may help to prevent future problems with the aorta or other health issues.
Could this study be right for you?
Inclusion:
- Age > 21 years
- Stanford type B aortic dissection not involving the aorta at or proximal to the innominate artery, without rupture and/or malperfusion (renal, mesenteric, or extremity)
- Acuity: within 48 hours – 6 weeks of index admission
Exclusion criteria:
- Ongoing systemic infection
- Pregnant or planning to become pregnant in the next 3 months
- Life expectancy related to non-aortic conditions < 2 years
- Prior surgery for aortic dissection
Age Range
21 years and up -
AAA-SHAPE Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion
Official Title AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of ExpansionPurpose
The purpose of this research is to determine if the IMPEDE-FX RapidFill System is safe and helps to shrink abdominal aortic aneurysm (AAA - a bulge or swelling due to weakening of the walls of the aorta, which is the main blood vessel that carries blood from your heart to other parts of your body) sacs after an endovascular stent graft (a fabric tube supported by metal wire stents that reinforces a weakened aorta) has been placed. The IMPEDE-FX RapidFill System used in this study is classified as investigational, which means it has not been approved by the Food and Drug Administration (FDA).
Could this study be right for you?
Inclusion:
- A candidate for elective EVAR of an infrarenal fusiform aortic aneurysm ≥5.5 cm in diameter in men and ≥ 5.0 cm in women
- Thrombus burden (percentage of the AAA sac occupied by thrombus) <50%, based on pre-procedure CTA
- Maximum Lumen diameter within the AAA sac of ≥40mm
- The predicted minimum number of IMPEDE-FX RapidFill Implants for the subject is ≤200
Exclusion:
- An inability to provide informed consent
- Enrolled in another clinical study that could interfere with the outcomes being studied in this trial
- Unable or unwilling to comply with study follow-up requirements
Inclusion and Exclusion Criteria varies, please contact Study Coordinator for more information.
Age Range
18 years and up -
Operating microscope versus traditional dental loupes - improving the view of dental surgery to save dental implants.
Official Title Operating Microscope versus Traditional Loupes during Regeneration Therapy for Peri-implantitis: A Randomized Controlled Trial with Ultrasonographic and Biomarkers EvaluationPurpose
The purpose of this study is to compare the one-year outcomes of treating peri-implantitis with periodontal surgical means between the use of an Operating Microscope and dental loupes.
This study includes the comparisons of the changes of inflammation of the gums, the bacteria present, and wound healing at the surgical site between the two methods. The hypothesis is that the use of the operating microscope, compared to dental loupes, is associated with better bacteria removal, quicker inflammatory resolution, and improved wound healing, which will contribute to better outcomes.
This study is 15 months, but your actual appointment time in the study, outside of the surgery itself, will be 6 – 9 hours. This will be in 6 study visits of 60 – 90 minutes in length.
Could this study be right for you?
Inclusion criteria: Participant has at least one implant indicated for peri-implant regenerative treatment.
Exclusion criteria: Participant has known systemic conditions and medication interactions that can affect healing of the surgical site.
Age Range
18 - 99 years -
Long-term Follow-up of Adults Who Experience an out of Hospital Cardiac Arrest
Official Title Patterns Of Survivors’ Recovery Trajectories in the ICECAP trial POST-ICECAPPurpose
The purpose of this study is to describe the physical, neuropsychological outcomes of adults who have experienced an outside of hospital cardiac arrest; and examine any associations between those outcomes and any clinical and/or rehabilitative interventions and/or social determinants of health.
Could this study be right for you?
- Experienced a coma after resuscitation from a cardiac arrest
- Received targeted/controlled body temperature management
- Survived to at least 1 month after experiencing a outside of hospital cardiac arrest
Age Range
18 years and up -
A Study about How Essential Oil Inhalers and a Wearable TENS Unit Affect Nausea and Stress
Official Title AROMA-NT: Assessment of the Mechanisms of Action of Inhaled Essential Oils and Wearable TENS unit device on NauseaPurpose
The purpose of this research study is to understand how a combination of two aromatic inhalers containing a blend of essential oils and a wearable TENS unit affects nausea and stress in those suffering from chronic nausea and anxiety.
Could this study be right for you?
- Able to understand English
- Nausea going on for longer than 6 months
Age Range
18 - 80 years -
Decay of HIV-1 Reservoirs in Participants on Long-Term ART
Official Title Decay of HIV-1 Reservoirs in Participants on Long-Term Antiretroviral Therapy: The ACTG HIV Reservoirs Cohort (AHRC) StudyPurpose
The purpose of this study is to examine longitudinal changes in HIV-1 reservoirs among participants with HIV-1 who are either currently receiving antiretroviral therapy (ART) or who received ART previously. Participants will undergo blood and hair sample collections for immunologic, virologic, and pharmacologic evaluations to study HIV-1 reservoirs in the body.
Could this study be right for you?
This study is currently only enrolling in Group 6 which includes participants who acquired HIV while taking long-acting cabotegravir (CAB).
Age Range
18 years and up -
Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined with ART Initiation during Acute HIV Infection to Induce HIV Remission
Official Title A Double-Blind, Randomized, Placebo-Controlled Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined with ART Initiation during Acute HIV Infection to Induce HIV RemissionPurpose
The purpose of this study is to evaluate the safety and efficacy of combination bNAbs in addition to ART initiated during acute HIV infection and to evaluate the impact on HIV viral reservoirs.
Could this study be right for you?
- Newly diagnosed HIV+ individuals who have not yet started antiretroviral therapy (ART)
- Willingness to start ART at enrollment
- Ability and willingness to participate in scheduled study visits and analytic treatment interruption (ATI)
- Weight <115kg
Age Range
18 - 70 years -
Pramipexole versus Escitalopram to Treat Comorbid HAND and MDD in HIV Infection
Official Title An Open-Label, Randomized Controlled Trial of Pramipexole versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD with Mild Neurocognitive Disorder (MND) in Persons Living with HIVPurpose
This study will evaluate the safety & efficacy of pramipexole vs. escitalopram for treatment of major depressive disorder (MDD) and comorbid MDD/mild neurocognitive disorder (MND) in people living with HIV.
Could this study be right for you?
- People living with HIV ages 18-70
- Diagnosis of MDD alone or with comorbid MDD/MND
- On ART for at least 3 months with HIV RNA <200 copies within 90 days
Age Range
18 - 70 years -
Therapeutic Vaccines in Combination with TRL-7 Agonist and bNAbs in Adults on Suppressive ART during Acute HIV-1
Official Title A Phase I/IIa Randomized, Placebo-Controlled Trial of Conserved-Mosaic T-cell Vaccine in a Regimen with Vesatolimod and Broadly Neutralizing Antibodies in Adults Initiated on Suppressive Antiretroviral Therapy during Acute HIV-1Purpose
This study will evaluate the safety and efficacy of these treatments in individuals with HIV-1 who started suppressive antiretroviral therapy (ART) during acute HIV-1 infection. The study consists of four steps including an analytical treatment interruption (ATI).
Could this study be right for you?
- Individuals with HIV who started treatment during acute HIV infection
- No known ART interruption >14 consecutive days since ART initiation
- Willingness to participate in analytic treatment interruption
- CD4 count ≥500 within 60 days to study entry
- HIV RNA <50 since initial viral suppression on ART and for at least 1 year prior to study entry
Age Range
18 years and up